Across TCGA pan-cancer cohorts, ELOVL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELOVL2 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ELOVL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOVL2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, LUAD, and SKCM are the cancer types where ELOVL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.220	0.541	.032	18	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	12	view →
SKCM	OS	Median	II,III,IV	1.000	0.725	.027	11	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ELOVL2 tumor-vs-normal RNA expression · all ELOVL2 data types